CORDIS
EU research results

CORDIS

English EN

Discovery and preclinical development of new generation tuberculosis vaccines

Objective

With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current control measures the Millennium Development Goals (MDGs) set for 2015 may be achieved, reaching these would still leave a million people per year dying from TB. Much more effective measures, particularly more effective vaccines will be essential to reach the target of eliminating TB in 2050. Two successive FP5 and FP6 funded projects, Tuberculosis (TB) Vaccine Cluster (2000-2003) and TBVAC (2004-2008), have in the recent decade made significant contributions to the global TB vaccine pipeline, with four vaccines (out of nine globally) being advanced to clinical stages. Both projects strongly contributed to the strengthening and integration of expertise and led to a European focus of excellence that is unique in the area of TB vaccine development. In order to sustain and accelerate the TB vaccine developments and unique integrated excellence of TBVAC, a specific legal entity was created named TuBerculosis Vaccine Initiative (TBVI). The NEWTBVAC proposal is the FP7 successor of TBVAC, and will be coordinated by TBVI. The proposal has the following objectives : 1) To sustain and innovate the current European pipeline with new vaccine discoveries and advance promising candidates to clinical stages; 2) To design new, second generation vaccines based new prime-boost strategies and/or new (combinations of) promising subunit vaccines, that will impact on reduction of disease in exposed individuals; 3) To sustain and innovate discovery, evaluation and testing of new biomarkers, that will be critically important for future monitoring of clinical trials.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Address

Runderweg 6
8219 Ph Lelystad

Netherlands

Activity type

Other

EU Contribution

€ 1 052 419

Administrative Contact

Jelle Thole (Dr.)

Participants (34)

Sort alphabetically

Sort by EU Contribution

Expand all

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 815 000

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 200 000

UNIVERSITAET ULM

Germany

EU Contribution

€ 425 800

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 573 000

INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE

Belgium

EU Contribution

€ 199 800

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

EU Contribution

€ 150 000

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 497 000

UNIVERSITATSSPITAL BASEL

Switzerland

EU Contribution

€ 188 000

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 167 100

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 542 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 626 575

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 185 000

ASTON UNIVERSITY

United Kingdom

EU Contribution

€ 185 000

INSTITUT PASTEUR DE LILLE FONDATION

France

EU Contribution

€ 379 500

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 317 000

INSTITUT PASTEUR

France

EU Contribution

€ 586 000

INSTITUT PASTEUR KOREA

South Korea

UNIVERSIDAD DE ZARAGOZA

Spain

EU Contribution

€ 430 143

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 794 000

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 299 600

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

EU Contribution

€ 200 000

Public Health England an Executive Agency of the Dept of Health

United Kingdom

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Netherlands

EU Contribution

€ 778 000

YONSEI UNIVERSITY

South Korea

INTERNATIONAL VACCINE INSTITUTE

South Korea

STICHTING WAGENINGEN RESEARCH

Netherlands

EU Contribution

€ 145 000

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL

Spain

EU Contribution

€ 244 366

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 524 000

UNIVERSITA DEGLI STUDI DI PALERMO

Italy

EU Contribution

€ 143 000

FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA

Switzerland

EU Contribution

€ 141 948

PX'Therapeutics

France

EU Contribution

€ 50 000

MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT

Netherlands

EU Contribution

€ 27 499

VAKZINE PROJEKT MANAGEMENT GMBH

Germany

EU Contribution

€ 100 000

Department of Health

United Kingdom

EU Contribution

€ 1 029 980

Project information

Grant agreement ID: 241745

Status

Closed project

  • Start date

    1 January 2010

  • End date

    28 February 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 18 995 943,60

  • EU contribution

    € 11 996 730

Coordinated by:

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Netherlands

This project is featured in...